menu
    • menu
    [{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"BMX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onward Therapeutics \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Onward Therapeutics \/ Onward Therapeutics"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"EMERCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"NK-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onward Therapeutics \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Onward Therapeutics \/ Onward Therapeutics"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OT-A201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onward Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onward Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OT-A201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onward Therapeutics \/ Biomunex Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Onward Therapeutics \/ Biomunex Pharmaceutical"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"EMERCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OT-C001","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onward Therapeutics \/ Emercell","highestDevelopmentStatusID":"5","companyTruncated":"Onward Therapeutics \/ Emercell"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onward Therapeutics \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Onward Therapeutics \/ Onward Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Onward Therapeutics

    Menu

    Onward Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OT-C001,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : EMERCell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Onward Therapeutics gets IMPD OK to Start Allogeneic NK Cell Study

                            Details : OT-C001 is an optimized cell therapy product consisting of highly activated & allogeneic NK cells. It is being evaluated for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 21, 2025

                            Lead Product(s) : OT-C001,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : EMERCell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OT-A201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Biomunex Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biomunex Starts Phase 1 Trial for First-in-class Bispecific Antibody in Cancer Treatment

                            Details : OT-A201 is a first-in-class bispecific antibody, which is currently being evalauted in phase 1 clinical trials for the treatment of hematological malignancy & solid tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2024

                            Lead Product(s) : OT-A201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Biomunex Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OT-A201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

                            Details : OT-A201 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : OT-A201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NK-001,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : EMERCell

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            EMERCell Signs Strategic Partnership with Onward Therapeutics for the Development of its NK Cell Therapy Techn...

                            Details : Onward will assist EMERCell to scale up their patented process of activation and amplification of allogeneic NK cells which includes one of EMERCell's lead drug candidates, NK-001 and to conduct clinical investigations.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 17, 2021

                            Lead Product(s) : NK-001,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : EMERCell

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMX-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Biomunex Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Bis...

                            Details : Biomunex and Onward will jointly develop, in a preclinical and early clinical program (BMX-101), a ‘first-in-class’ immunotherapeutic bispecific antibody, in hematological malignancies, developed by bi- and multi-specific antibody platform BiXAb.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : BMX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Biomunex Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Onward Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Biomunex Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Onward Therapeutics and Biomunex Ink Worldwide Exclusive License and Co-development Deal to a Bispecific Antib...

                            Details : Biomunex grants the rights for Onward to pursue development, manufacture and commercialization of this first-in-class bispecific antibody. Onward and Biomunex will jointly develop the antibody during the preclinical and early clinical program.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 16, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Biomunex Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth